Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging

Completed

Conditions studied: Sarcoma

In brief

The purpose of this study is to determine the ability of a specific imaging method, termed Diffuse Optical Spectroscopic Imaging, to provide metabolic and functional information which can be used to predict overall response to preoperative (neoadjuvant) chemotherapy in patients with sarcomas. Sarcoma patients face comparatively poor response rates to chemotherapy and early, non-invasive indications of response could provide physicians with the information necessary to make evidence-based changes in treatment strategies. Patients who do not demonstrate early signs of response would be spared the unnecessary side-effects of an ineffective chemotherapy regimen, and could either be switched to a different regimen or undergo surgery

Key facts

Study ID

NCT01263405

Run by

University of California, Irvine

People needed

3

Starts

2010-12-01

Expected to finish

2014-10-01

Last updated by the study team

2022-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Any subjects with no current or previous history of sarcoma are eligible to be a normal volunteer
• Any subject with a sarcoma neoplasm is eligible to be measured for aim 2 of the study
• Only patients undergoing neoadjuvant chemotherapy for sarcoma are eligible for Aim 3 of the study

You may not qualify if…

• Age less that 18 year old

Where it is running

• Beckman Laser Institute — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.